Rubius Therapeutics, Inc.
We are pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs. Based on our vision that human red blood cells are the foundation of the next significant innovation in medicine, we have designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies.
$20.00 - $22.00
J.P. Morgan, Morgan Stanley, Jefferies, Leerink Partners
To view the prospectus for Rubius Therapeutics, Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253